Ultrasound contrast agent reviews should be stayed pending FDA decision on drug/device status -- Bracco.
ULTRASOUND CONTRAST AGENT NDA/PMA ACTIONS SHOULD BE STAYED until FDA determines whether the agents should be regulated as drugs or devices, Bracco Diagnostics asserts in a Jan. 30 petition filed on behalf of the company by D.C. law firm Kleinfeld, Kaplan & Becker. Bracco requests that FDA "stay any action," including the "review or approval of any pending PMAs or NDAs for ultrasound contrast agents or the convening of an advisory committee meeting on this topic."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth